IMUNON to Participate in Upcoming Investor Conferences

IMUNON, Inc. (Nasdaq: IMNN) announced its CEO will participate in the Maxim Growth Summit and ThinkEquity Conference in October 2026. The company is a clinical-stage biotech firm developing DNA-mediated immunotherapies, with a focus on advanced ovarian cancer treatment and a COVID-19 booster vaccine.

Original reporting
Published Oct 8, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 1:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$IMNN
Neutral
medium confidence
Mentioned
$IMNN
Relevance
4/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$IMNNNeutralLow
01

Why it matters

The announcement provides visibility but does not introduce new financial data or catalysts, resulting in neutral market impact.

02

Market read

Limited relevance; primarily informational for investors tracking upcoming presentations.

03

What to watch

Potential networking outcomes or partnership announcements could arise from the conferences.

Relevance 4/10Novelty 2/10Timing: upcoming conferences in mid‑October

Background

Press release announcing IMUNON's participation in upcoming investor conferences.

Company-level read

Ticker impact

$IMNNNeutralMedium confidence
Context

IMUNON announced its CEO will present at two investor conferences in October, indicating upcoming investor outreach.

Expected impact

likely little immediate impact as the news is informational

Evidence & confidence

Conference participation does not change fundamentals, so price likely unchanged.

Market effects

minimal effect on biotech sector

limited to US investors following the events

low

Counterpoint

Investors might view the outreach as a sign of need for capital, but no concrete catalyst is present.

Key entities

  • IMUNON, Inc.

    Clinical‑stage biotechnology company developing DNA‑mediated immunotherapies.

  • Stacy Lindborg, Ph.D.

    President and Chief Executive Officer of IMUNON.

Related articles

$IMNNMedAI 8/10

Imunon (IMNN) Q3 2026 Earnings Call Transcript

Imunon (IMNN) reported Q3 2026 progress, highlighting Phase III IMNN-001 study for ovarian cancer. The company saw strong enrollment, independent validation, and a partnership with the National Cancer Institute. IMNN-001 aims to address a disease with low survival rates and limited treatment advances. The company expects 50% enrollment by Q1 2028 and completion by Q1 2029, with interim analysis in Q1 2030.

$IMNNLow

Imunon 3Q 2026: EPS ($0.64) — 10-Q Summary

Imunon (IMNN) reported a wider net loss of $3.81M in Q3 2026, though diluted EPS improved to ($0.64) from ($1.16) YoY. Operating expenses decreased 1%, with R&D costs down 6%. The OVATION 3 trial enrollment exceeded expectations, and the company advanced its NCI collaboration and MRD study. Imunon discontinued PLACCINE and IMNN-101 development in Q1 2026.

$IMNNMed

Imunon Reports Q3 2026 Net Loss of $3.8 Million and Advances IMNN-001

Imunon reported a Q3 2026 net loss of $3.8M, or $0.64 per share, compared to $3.4M, or $1.16 per share, a year earlier. Operating expenses were $3.4M. The company updated its Phase 3 ovarian cancer study and other programs, with enrollment expected to complete by Q1 2029. Imunon also transferred ThermoDox rights to VoxelDox, contingent on funding.

$IMNNHighAI 8/10

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollm

$IMNNHighAI 8/10

IMUNON presents translational data from ovarian cancer trial

IMUNON Inc. (IMNN) presented data from its Phase 2 OVATION 2 study of IMNN-001 in advanced ovarian cancer, showing improved survival and immune response. The trial compared IMNN-001 with chemotherapy against chemotherapy alone. The company is now conducting a Phase 3 trial, OVATION 3, to confirm these results. IMNN-001 is a DNA-based immunotherapy targeting IL-12 delivery to tumor tissue.

$IMNNMed

In an ovarian cancer trial, median survival was 14.7 months longer with added treatment

IMUNON, Inc. (Nasdaq: IMNN) announced new data from its Phase 2 OVATION 2 study, showing that IMNN-001 increased anti-tumoral T-cell activity in ovarian cancer patients. The treatment improved median overall survival by 14.7 months compared to standard care. The findings support the ongoing Phase 3 OVATION 3 trial. The data was presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.